A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.
The simple test developed by University of Central Florida scientist Qun “Treen” Huo holds the promise of earlier detection of one of the deadliest cancers among men. It would also reduce the number of unnecessary and invasive biopsies stemming from the less precise PSA test that’s now used.
“It’s fantastic,” said Dr. Inoel Rivera, a urologic oncologist at Florida Hospital Cancer Institute, which collaborated with Huo on the recent pilot studies. “It’s a simple test. It’s much better than the test we have right now, which is the PSA, and it’s cost-effective.”
When a cancerous tumor begins to develop, the body mobilizes to produce antibodies. Huo’s test detects that immune response using gold nanoparticles about 10,000 times smaller than a freckle.
When a few drops of blood serum from a finger prick are mixed with the gold nanoparticles, certain cancer biomarkers cling to the surface of the tiny particles, increasing their size and causing them to clump together.
Among researchers, gold nanoparticles are known for their extraordinary efficiency at absorbing and scattering light. Huo and her team at UCF’s NanoScience Technology Center developed a technique known as nanoparticle-enabled dynamic light scattering assay (NanoDLSay) to measure the size of the particles by analyzing the light they throw off. That size reveals whether a patient has prostate cancer and how advanced it may be.
And although it uses gold, the test is cheap. A small bottle of nanoparticles suspended in water costs about $250, and contains enough for about 2,500 tests.
“What’s different and unique about our technique is it’s a very simple process, and the material required for the test is less than $1,” Huo said. “And because it’s low-cost, we’re hoping most people can have this test in their doctor’s office. If we can catch this cancer in its early stages, the impact is going to be big.”
Read more: $1 Test Developed at UCF Outperforms PSA Screening for Prostate Cancer
The Latest on: Prostate Cancer
[google_news title=”” keyword=”Prostate Cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prostate Cancer
- New Oral Treatment for Metastatic Prostate Cancer Can Help Prolong Lifeon June 9, 2023 at 1:31 pm
For men with BRCA-mutated metastatic castration-resistant prostate cancer, this new treatment option may significantly extend life.
- What Is Intermediate Risk Prostate Cancer?on June 9, 2023 at 10:25 am
Prostate cancer is one of the most common cancers in males. It begins in the prostate gland, which produces seminal fluid (part of semen). To better understand the likelihood of tumor growth ...
- Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate canceron June 9, 2023 at 7:40 am
Oncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Canceron June 9, 2023 at 6:16 am
to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging. In a study of high-risk patients with nonmetastatic castration-resistant ...
- How Common is Prostate Cancer in Transgender Women?on June 9, 2023 at 3:40 am
Prostate cancer may be more common among transgender women than previous case reports suggest. Read to get more ...
- Potential “Game Changer” Discovery for Prostate Cancer Therapyon June 9, 2023 at 1:42 am
Researchers have identified a previously unknown weak spot in prostate cancer cells that could also lead to entirely new therapeutic approaches for other types of cancer.
- Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutationson June 8, 2023 at 10:05 am
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic ...
- A potential milestone in cancer therapy: Team discovers weak spot in prostate cancer cellson June 8, 2023 at 8:00 am
Prostate cancer is the most common non-skin cancer in men worldwide. According to international estimates about one in six men will get prostate cancer during their lifetime and worldwide, over ...
- Can You Get a CT Scan for Prostate Cancer?on June 6, 2023 at 3:47 pm
Doctors do not usually use CT scans to diagnose prostate cancer, but they sometimes use them to see whether cancer has spread to other tissues. The survival rate of prostate cancer tends to be very ...
- Researchers work to make prostate-specific antigen test for cancer more accurateon June 5, 2023 at 7:30 am
Researchers think they've found a way to make the blood test for prostate-specific antigen (PSA) accurate enough to significantly reduce overdiagnosis and better predict dangerous cancers.
via Bing News